Patrick Deegan

6.2k total citations
96 papers, 2.4k citations indexed

About

Patrick Deegan is a scholar working on Physiology, Epidemiology and Molecular Biology. According to data from OpenAlex, Patrick Deegan has authored 96 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Physiology, 28 papers in Epidemiology and 26 papers in Molecular Biology. Recurrent topics in Patrick Deegan's work include Lysosomal Storage Disorders Research (77 papers), Trypanosoma species research and implications (24 papers) and Carbohydrate Chemistry and Synthesis (21 papers). Patrick Deegan is often cited by papers focused on Lysosomal Storage Disorders Research (77 papers), Trypanosoma species research and implications (24 papers) and Carbohydrate Chemistry and Synthesis (21 papers). Patrick Deegan collaborates with scholars based in United Kingdom, United States and Israel. Patrick Deegan's co-authors include Derralynn Hughes, Timothy M. Cox, Neal J. Weinreb, Atul Mehta, Carla E. M. Hollak, Özlem Göker-Alpan, Pramod K. Mistry, Bruno Bembi, Gregory M. Pastores and Nadia Belmatoug and has published in prestigious journals such as Blood, PLoS ONE and Hepatology.

In The Last Decade

Patrick Deegan

93 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Deegan United Kingdom	27	1.9k	711	683	595	510	96	2.4k
Marco Spada Italy	28	1.6k 0.9×	700 1.0×	415 0.6×	1.1k 1.9×	428 0.8×	132	3.1k
Deeksha Bali United States	36	2.1k 1.1×	624 0.9×	224 0.3×	937 1.6×	883 1.7×	109	4.1k
Anaïs Brassier France	19	714 0.4×	230 0.3×	294 0.4×	608 1.0×	168 0.3×	84	1.7k
Neal J. Weinreb United States	35	4.2k 2.2×	1.7k 2.3×	2.0k 2.9×	1.3k 2.2×	1.4k 2.8×	105	4.6k
Rebecca S. Wappner United States	19	1.2k 0.7×	552 0.8×	648 0.9×	897 1.5×	440 0.9×	39	2.2k
Maryam Banikazemi United States	20	3.6k 1.9×	1.7k 2.3×	861 1.3×	531 0.9×	1.0k 2.0×	36	4.0k
Tarekegn Geberhiwot United Kingdom	24	728 0.4×	305 0.4×	212 0.3×	528 0.9×	88 0.2×	89	1.5k
Filippo Pinto e Vairo Brazil	20	602 0.3×	211 0.3×	207 0.3×	569 1.0×	88 0.2×	111	1.4k
Catherine Rehder United States	24	694 0.4×	162 0.2×	64 0.1×	572 1.0×	194 0.4×	75	1.9k
Amel Karaa United States	24	394 0.2×	289 0.4×	145 0.2×	745 1.3×	41 0.1×	65	1.5k

Countries citing papers authored by Patrick Deegan

Since Specialization

Citations

This map shows the geographic impact of Patrick Deegan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Deegan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Deegan more than expected).

Fields of papers citing papers by Patrick Deegan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Deegan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Deegan. The network helps show where Patrick Deegan may publish in the future.

Co-authorship network of co-authors of Patrick Deegan

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Deegan. A scholar is included among the top collaborators of Patrick Deegan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Deegan. Patrick Deegan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Brand, Eva, Aleš Linhart, Patrick Deegan, et al.. (2025). Clinical management of female patients with Fabry disease based on expert consensus. Orphanet Journal of Rare Diseases. 20(1). 7–7. 5 indexed citations

2.

Zimran, Ari, Shoshana Revel‐Vilk, Tama Dinur, et al.. (2025). Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey. Orphanet Journal of Rare Diseases. 20(1). 43–43. 2 indexed citations

3.

Elstein, Deborah, Nadia Belmatoug, Bruno Bembi, et al.. (2024). Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry. Journal of Clinical Medicine. 13(12). 3588–3588. 2 indexed citations

4.

Colaço, Alexandria, Elias Adriaenssens, Lianne C. Davis, et al.. (2019). Mechanistic convergence and shared therapeutic targets in Niemann‐Pick disease. Journal of Inherited Metabolic Disease. 43(3). 574–585. 15 indexed citations

5.

Lau, Heather, Nadia Belmatoug, Pilar Giraldo, et al.. (2019). Long-term analysis of velaglucerase alfa-treated patients with Gaucher disease who entered the Gaucher Outcomes Survey (GOS) real-life registry. Molecular Genetics and Metabolism. 126(2). S91–S91. 2 indexed citations

6.

Vijapurapu, Ravi, Tarekegn Geberhiwot, Ana Jovanović, et al.. (2019). Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart. 105(23). 1825–1831. 14 indexed citations

7.

Collins, Lucy, et al.. (2018). The motor and cognitive features of Parkinson’s disease in patients with concurrent Gaucher disease over 2 years: a case series. Journal of Neurology. 265(8). 1789–1794. 11 indexed citations

8.

Guest, Julian F., Nadia Ayoub, Christian J. Hendriksz, et al.. (2018). Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom. PLoS ONE. 13(2). e0191945–e0191945. 3 indexed citations

9.

Deegan, Patrick, et al.. (2016). Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey. Blood Cells Molecules and Diseases. 68. 218–225. 18 indexed citations

10.

Pastores, Gregory M., Мilan Petakov, Pilar Giraldo, et al.. (2014). A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. 53(4). 1 indexed citations

11.

Pastores, Gregory M., Мilan Petakov, Pilar Giraldo, et al.. (2014). A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Molecules and Diseases. 53(4). 253–260. 46 indexed citations

12.

Balwani, Manisha, Catherine Breen, Gregory M. Enns, et al.. (2013). Clinical Effect And Safety Profile of Recombinant Human Lysosomal Acid Lipase in Patients With Cholesteryl Ester Storage Disease. Hepatology. 58(3). 950–957. 77 indexed citations

13.

Durán, Raquel, Niccolò E. Mencacci, Maryam Shoai, et al.. (2012). The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders. 28(2). 232–236. 102 indexed citations

14.

Hughes, Derralynn, Patrick Deegan, Perry Elliott, et al.. (2012). Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease. Journal of Medical Genetics. 49(3). 212–220. 19 indexed citations

15.

Fasano, Tommaso, Paolo Zanoni, Claudio Rabacchi, et al.. (2012). Novel mutations of ABCA1 transporter in patients with Tangier disease and familial HDL deficiency. Molecular Genetics and Metabolism. 107(3). 534–541. 29 indexed citations

16.

Deegan, Patrick, Elena Pavlova, Penelope E. Stein, et al.. (2010). Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy. Medicine. 90(1). 52–60. 93 indexed citations

17.

Whitfield, Phillip D., J Calvin, S. Hogg, et al.. (2005). Monitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramide. Journal of Inherited Metabolic Disease. 28(1). 21–33. 69 indexed citations

18.

Lim, Pitt, Nikolaos Tzemos, C A J Farquharson, et al.. (2002). Reversible hypertension following coeliac disease treatment: the role of moderate hyperhomocysteinaemia and vascular endothelial dysfunction. Journal of Human Hypertension. 16(6). 411–415. 20 indexed citations

19.

Deegan, Patrick, et al.. (1995). Intestinally derived lipoprotein particles in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia. Acta Diabetologica. 32(4). 244–250. 7 indexed citations

20.

Deegan, Patrick, et al.. (1994). Alterations in apolipoprotein B-48 in the postprandial state in NIDDM. Diabetologia. 37(12). 1259–1264. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact